Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Viral loads of Delta-variant SARS-CoV2 breakthrough infections following vaccination and booster with the BNT162b2 vaccine

View ORCID ProfileMatan Levine-Tiefenbrun, View ORCID ProfileIdan Yelin, Hillel Alapi, Rachel Katz, Esma Herzel, Jacob Kuint, Gabriel Chodick, Sivan Gazit, Tal Patalon, View ORCID ProfileRoy Kishony
doi: https://doi.org/10.1101/2021.08.29.21262798
Matan Levine-Tiefenbrun
1Faculty of Biology, Technion - Israel Institute of Technology, Haifa, Israel
2Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Matan Levine-Tiefenbrun
Idan Yelin
1Faculty of Biology, Technion - Israel Institute of Technology, Haifa, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Idan Yelin
Hillel Alapi
3Maccabitech, Maccabi Health Services, Tel Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rachel Katz
3Maccabitech, Maccabi Health Services, Tel Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Esma Herzel
3Maccabitech, Maccabi Health Services, Tel Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacob Kuint
2Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
3Maccabitech, Maccabi Health Services, Tel Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gabriel Chodick
2Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
3Maccabitech, Maccabi Health Services, Tel Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sivan Gazit
3Maccabitech, Maccabi Health Services, Tel Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tal Patalon
3Maccabitech, Maccabi Health Services, Tel Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: patalon_t@mac.org.il rkishony@technion.ac.il
Roy Kishony
1Faculty of Biology, Technion - Israel Institute of Technology, Haifa, Israel
4Faculty of Computer Science, Technion - Israel Institute of Technology, Haifa, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Roy Kishony
  • For correspondence: patalon_t@mac.org.il rkishony@technion.ac.il
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

The BNT162b2 vaccine showed high real-life effectiveness both at preventing disease and in reducing viral loads of breakthrough infections, but coincidental with the rise of the Delta-variant SARS-CoV2, these protective effects have been decreasing, prompting a third, booster, vaccine inoculation. Here, analyzing viral loads of over 11,000 infections during the current wave in Israel, we find that even though this wave is dominated by the Delta-variant, breakthrough infections in recently vaccinated patients, still within 2 months post their second vaccine inoculation, do have lower viral loads compared to unvaccinated patients, with the extent of viral load reduction similar to pre-Delta breakthrough observations. Yet, this infectiousness protection starts diminishing for patients two months post vaccination and ultimately vanishes for patients 6 months or longer post vaccination. Encouragingly, we find that this diminishing vaccine effectiveness on breakthrough infection viral loads is restored following the booster vaccine. These results suggest that the vaccine is initially effective in reducing infectiousness of breakthrough infections even with the Delta variant, and that while this protectiveness effect declines with time it can be restored, at least temporarily, with a booster vaccine.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by the Israel Science Foundation (grant no. 3633/19 to R. Kishony and G.C.) as part of the KillCorona-Curbing Coronavirus Research Program.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the MHS (Maccabi Healthcare Services) Institutional Review Board (IRB). Due to the retrospective design of the study, informed consent was waived by the IRB, and all identifying details of the participants were removed before computational analysis.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

According to the Israel Ministry of Health regulations, individual-level data cannot be shared openly. Specific requests for remote access to de-identified community-level data should be directed to KSM, Maccabi Healthcare Services Research and Innovation Center.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted September 01, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Viral loads of Delta-variant SARS-CoV2 breakthrough infections following vaccination and booster with the BNT162b2 vaccine
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Viral loads of Delta-variant SARS-CoV2 breakthrough infections following vaccination and booster with the BNT162b2 vaccine
Matan Levine-Tiefenbrun, Idan Yelin, Hillel Alapi, Rachel Katz, Esma Herzel, Jacob Kuint, Gabriel Chodick, Sivan Gazit, Tal Patalon, Roy Kishony
medRxiv 2021.08.29.21262798; doi: https://doi.org/10.1101/2021.08.29.21262798
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Viral loads of Delta-variant SARS-CoV2 breakthrough infections following vaccination and booster with the BNT162b2 vaccine
Matan Levine-Tiefenbrun, Idan Yelin, Hillel Alapi, Rachel Katz, Esma Herzel, Jacob Kuint, Gabriel Chodick, Sivan Gazit, Tal Patalon, Roy Kishony
medRxiv 2021.08.29.21262798; doi: https://doi.org/10.1101/2021.08.29.21262798

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (240)
  • Allergy and Immunology (521)
  • Anesthesia (125)
  • Cardiovascular Medicine (1420)
  • Dentistry and Oral Medicine (217)
  • Dermatology (158)
  • Emergency Medicine (291)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (584)
  • Epidemiology (10297)
  • Forensic Medicine (6)
  • Gastroenterology (527)
  • Genetic and Genomic Medicine (2629)
  • Geriatric Medicine (254)
  • Health Economics (497)
  • Health Informatics (1733)
  • Health Policy (789)
  • Health Systems and Quality Improvement (673)
  • Hematology (266)
  • HIV/AIDS (565)
  • Infectious Diseases (except HIV/AIDS) (12093)
  • Intensive Care and Critical Care Medicine (649)
  • Medical Education (273)
  • Medical Ethics (83)
  • Nephrology (289)
  • Neurology (2461)
  • Nursing (145)
  • Nutrition (377)
  • Obstetrics and Gynecology (493)
  • Occupational and Environmental Health (568)
  • Oncology (1324)
  • Ophthalmology (401)
  • Orthopedics (146)
  • Otolaryngology (237)
  • Pain Medicine (168)
  • Palliative Medicine (51)
  • Pathology (343)
  • Pediatrics (780)
  • Pharmacology and Therapeutics (330)
  • Primary Care Research (296)
  • Psychiatry and Clinical Psychology (2397)
  • Public and Global Health (5007)
  • Radiology and Imaging (893)
  • Rehabilitation Medicine and Physical Therapy (528)
  • Respiratory Medicine (681)
  • Rheumatology (309)
  • Sexual and Reproductive Health (256)
  • Sports Medicine (245)
  • Surgery (298)
  • Toxicology (45)
  • Transplantation (140)
  • Urology (108)